Document:

Convertible Bonds Terms and Conditions dated September 30, 2004

 Exhibit 4.32 
  
 GPC Biotech AG 
 Martinsried/Planegg 
  
 Convertible Bonds Terms and Conditions 
  
 for executives (Führungskräfte) of the Company and its
affiliated subsidiary companies (nachgeordnete verbundene Unternehmen) in Germany and abroad 
  
 (Resolution of the General Meeting of August 31, 2004) 
  
 Preamble 
  
 The General Meeting of GPC Biotech AG (hereinafter “the Company” or “GPC”) resolved on August 31, 2004 to implement a program for the issuance of convertible bonds, nominal value € 1,00 per convertible bond (the “Convertible Bonds”) to members of the management bodies and executives (Führungskräfte) of the
Company and its affiliated subsidiary companies (nachgeordnete verbundene Unternehmen) in Germany and abroad (hereinafter the “Allottees”). 
  
 The terms and conditions of the program for the issuance of Convertible Bonds are as follows: 
  
 § 1 
 Convertible Bonds

  

	(1)	The Allottees receive registered conversion privileges which comprise the right to purchase ordinary no-par value bearer Shares (the “Shares”) of the Company in the number listed in
the offer letter or in the convertible bond certificate, subject to adjustment pursuant to § 9 hereof. The Convertible Bonds are issued under the condition that the resolution of the shareholder meeting on August 31, 2004, which refers to the
conditional capital (Item 7), will be registered in the commercial register of Munich. If this resolution is declared void by a legally binding court decision the Convertible Bonds will definitely not come into being. In this case the Allottee is
entitled to claim back the paid-in nominal amount with an interest rate of 3.5% per annum. 

  

	(2)	By accepting the offer to purchase the Convertible Bonds, the Allottee shall transfer the total nominal amount of the Convertible Bonds to which he/she is entitled in Euros for unconditional
disposition by the Company and without further costs to an account to be specified by the Company. The transfer has been made no later than one month after the grant date. 

  

	(3)	The Convertible Bonds may be evidenced in several registered global convertible bond certificates. The right to (individual) convertible bond certificates is excluded.

  

	(4)	 On behalf of the Company, a bonds register entitled “Convertible Bonds” (hereinafter the “Options Register”), in which the Convertible Bonds are
registered together with the conversion price (see § 8 (1) hereof), the series and number as well as the holder by name, date of birth, residence address and occupation, will be maintained by the exercise agent (see § 18 hereof). 

	 	 
In addition, the Options Register sets forth in particular the information necessary for determining the period according to § 14 (1) hereof (the “Vesting
Period”). 

  

	(5)	In relation to the Company, only parties registered as Allottees in the Options Register are qualified as such. 

  
 § 2 Basic 
 Features of
the Convertible Bonds 
  

	(1)	As provided by these terms and conditions, and subject to any adjustment pursuant to §§ 8 and 9 hereof, the Convertible Bonds may be exercised to obtain one Share of the Company for
each Convertible Bond upon payment of the conversion price to be specified by the Company in accordance with § 8 hereof. 

  

	(2)	To cover the Convertible Bonds to be issued to the Allottees, the August 31, 2004 General Meeting of the Company created a conditional capital in the amount of up to € 950,000. The Management Board of the Company may choose, in agreement with the Supervisory Board, whether the Shares underlying the
Convertible Bonds will be made available from such conditional capital or from a program to repurchase its own Shares, resolved or possibly yet to be resolved by the General Meeting. 

  
 § 3 
 Interest Rate, Repayment of the Nominal Amount 
  

	(1)	The Convertible Bonds bear interest at 3.5% per annum starting from the date of their issuance. The interest amounts are due at the end of the respective calendar year. In the event of the
cancellation of the conversion privileges pursuant to § 14 hereof or of the due exercise of the conversion privileges pursuant to § 10 hereof, the interest amounts for the current calendar year are due immediately.

  

	(2)	A right to compound interest does not exist. 

  

	(3)	The paid-in nominal amount is due for repayment within ten calendar days after lapse of the conversion privileges for whatever reason. 

  
 § 4 
 Purchasing Periods, Time to Maturity 
  

	(1)	The Convertible Bonds may be offered to the Allottees for subscription within the last fifteen business days of each calendar month. The date of issuance is the day on which the Management
Board has made an offer to the Allottee for subscription of the Convertible Bonds, provided, such offer has been accepted within the subscription period. 

  

	(2)	The time to maturity of the conversion privileges is ten years from the date of their issuance. 

	 	§ 3(3) notwithstanding, the conversion privileges lapse without compensation upon expiration of the time to maturity. 

  

 2 

 § 5 
 Waiting Period 
  
 The Allottees may exercise the conversion privileges at
the earliest after the expiration of two years following their issuance pursuant to § 4 (1) hereof. Debentures, each percentage shall be rounded down to the next smaller whole number. After the expiration of the waiting period and subject (i)
to the above restrictions and (ii) any additional mandatory legal provisions, the exercise of the conversion rights shall be permitted until the end of their term on any banking day in Frankfurt am Main. In addition, the conversion privileges may
only be exercised if, after expiration of the two-year waiting period, the cancellation periods set forth in § 14 (1) hereof, as specified by the Company in the offer letter or in the (global) convertible bond certificates, have expired.

  
 § 6 
 Exercise Periods 
  

	(1)	Conversion privileges may not be exercised on or after the day on which the Company announces an offer to its shareholders to subscribe for new Shares or bonds with conversion privileges or
option rights attached to them by letter to all shareholders or by a notice published in the (Bundesanzeiger) of the Federal Republic of Germany, until the day on which the Shares are quoted for the first time as “ex subscription
rights” on the Frankfurt Stock Exchange. 

  

	(2)	Notwithstanding § 6 (1) hereof, the conversion privileges may only be exercised in the six weeks following publication of the quarterly reports or of the annual financial statement
respectively. The conversion privileges may not be exercised from December 24 to December 31 of each calendar year. 

  

	(3)	The Management Board has the right to impose further restrictions on the exercise periods. 

  
 § 7 
 Performance Goals

  
 Notwithstanding §§ 4 and 5 hereof, the conversion privileges may only be
exercised if the Closing Price develops better than a reference index. The reference index shall be the Prime IG Biotechnology Index of the Frankfurt Stock Exchange (the “Price Index”). The Price Index and the Closing Price on the date on
which the Convertible Debentures are issued shall serve as the starting point for the performance measurement. The Convertible Debentures may only be exercised if the Closing Price has developed better than the Price Index. The relevant comparison
date for this shall be the date four weeks prior to the exercise of the subscription rights. 
  
 § 8 
 Conversion Price 
  

	(1)	As provided by these terms and conditions, each conversion privilege represents the right to subscribe for one Share. The conversion price to be paid upon exercise of the conversion privilege
for the subscription of one individual Share corresponds to the average closing price of the GPCB Shares in the XETRA closing auction on the Frankfurt Stock Exchange (the “Closing Price”) during the last five exchange trading days prior to
the issuance of the Convertible Debentures less € 1.00; 

  

 3 

 
The conversion price will be adjusted in accordance with these terms and conditions if the Company implements certain capital measures during the time to maturity of
the conversion privileges or grants further option rights or conversion privileges to its shareholders. The purpose of such adjustment is to ensure that equivalence of the conversion price as well as of the exercise hurdles is maintained even after
completion of such measures and the related impact on the Share price. 
  

	(2)	Effective on such date on which the Shares are initially quoted “ex subscription right” the conversion price shall be reduced pursuant to the immediately following paragraph, but in
no case to less than the pro rata amount of the Share capital attributable to one Share (at least 

	 	€ 1.00). 

  

	(3)	The conversion price shall be reduced if, during the time to maturity of the Convertible Bonds, new Shares or warrants or Convertible Bonds with option rights or conversion privileges to
Shares attached to them are issued a capital increase or if the Company disposes of its own Shares and in connection with subscription rights to any such securities are granted to the existing shareholders of the Company. The conversion price will
be reduced of the ratio of 

  

	 	(1)	the arithmetic average of the Shares as traded “ex subscription right” on the Frankfurt Stock Exchange on all days so traded and 

  

	 	(2)	the closing price of the Shares on the last stock exchange trading day immediately prior to the commencement of trading “ex subscription right”. 

  

	(4)	The Company shall, simultaneously with the publication of the offer to its existing shareholders to subscribe for any new Shares or bonds with conversion privileges or option rights attached
to them, the issuance of which triggers the reduction of the conversion price, notify the Allottees in writing of the conversion price as reduced pursuant to § 8(3) and of the date on which the Shares are initially quoted “ex-subscription
rights” on the Frankfurt Stock Exchange, from which date onward the reduced conversion price shall be effective. 

  

	(5)	As stipulated by § 218 AktG, in the case of a capital increase from corporate funds, an existing conditional capital is increased in the same ratio as the share capital. The conversion
ratio according to § 2 hereof is increased in the same ratio. Fractions of Shares created as a result of the capital increase from corporate funds are not considered in the exercise of Convertible Bonds. 

  

	(6)	The conversion price will not be reduced if the Company, in adopting the resolution on the issuance of new Shares or of bonds with conversion privileges or option rights attached to them or
on the disposal of its own Shares also grants the Allottees a direct or indirect subscription right that corresponds to the value of the subscription right of the existing shareholders. 

  
 § 9 
 Adjustment of the Conversion Privileges 
  

	(1)	 In the case of (1) a merger of the Company with and into another company, (2) a reorganization of the Company, (3) a change in the calculated nominal value of the Shares or
(4) comparable measures that impair the rights of the Allottees by abolishing or changing the underlying Shares according to these terms and conditions, the Convertible Bonds are replaced by the right to purchase, at the base price, that number,
respectively, of Shares, equity interests or any other interests in the Company or its legal successors that 

  

 4 

	 	 
otherwise substitute the Shares of the Company whose value corresponds to the market value of the Shares of the Company on the date on which such measure is
implemented. In all other respects these terms and conditions shall remain applicable without restriction. 

  

	(2)	In the case of a capital reduction by grouping of Shares (§ 222(4) AktG) or by redemption of Shares (§ 237 AktG), the conversion ratio is adjusted by multiplying it with the factor
calculated by dividing the number of Shares after the capital reduction by the number of Shares before the capital reduction. Fractions of Shares created as a result of a capital reduction are not made available for exercise of the conversion
privileges. 

  

	(3)	Until the due exercise of the convertible bonds, the Allottees have no rights to dividends or other distributions from the Shares underlying the Convertible Bonds. 

 
 § 10 
 Exercise Procedure; Issuance of Underlying Shares 
  

	(1)	To exercise the conversion privileges, the Allottee must 

  

	 	a)	enter the number of conversion privileges to be exercised as well as the exercise date in the original convertible bond certificate. In addition, the exercise is to be signed by the Allottee
in the original convertible bond certificate and countersigned by the Company; 

  

	 	b)	using the form available from the exercise agent or from a trustee (see § 18 hereof), if such is appointed for the purpose, deliver a written subscription declaration in duplicate to the
exercise agent or to the trustee; and 

  

	 	c)	pay the conversion price in EURO, completely and free of costs and charges to the Company, to the Company’s account indicated in the subscription declaration form.

  

	(2)	Declarations received by the exercise agent within the periods set forth in §§ 5 and 6 hereof are deemed to be delivered and received on the next subsequent banking business day on
which the exercise of the convertible bond is again permissible. The Allottee may revoke his/her subscription declaration only so long as receipt has not yet effectively taken place. 

  

	(3)	The Shares resulting from the exercise of the conversion privileges are printed and delivered in the form provided by the Articles of Association of the Company in their respective valid
version. Issuance takes place – to the extent possible and subject to receipt by the Company of payment in full of the conversion price – within ten banking business days after the subscription declaration becomes effective.

  

	(4)	In the event that the Allottee intends to sell the Shares acquired through the exercise of his/her conversion privileges immediately after such acquisition, the Company may, with a view to a
smooth placement in the market, tender, in a manner that safeguards the interests of the Allottees, the Shares created from a large number of exercises in the form of a block sale to (for example) institutional investors. The Allottee shall, at the
request of the Company, assist appropriately and reasonably in the smooth placement on the market. 

  

	(5)	Any issuance of Shares resulting from the exercise of conversion privileges is only permitted in conformity with the terms and conditions hereof and in no case prior to payment in full of the
conversion price according to § 8 hereof (see § 199(1) AktG). 

  

 5 

 § 11 
 Dividend Entitlement of the New Shares 
  
 The Shares created through the
exercise of conversion privileges – provided they are created through exercise before the beginning of the General Meeting of the Company that resolves on the allocation of balance sheet profits – are entitled to dividends from the
beginning of the previous fiscal year, or, to the extent created through exercise after the beginning of General Meeting of the Company, the respective fiscal year in which they were created through such exercise. 
  
 § 12 
 Nonassignability of the Convertible Bonds 
  

	(1)	In principle, the Convertible Bonds may not be transferred. 

  

	(2)	Other methods of disposing of the Convertible Bonds, granting of subordinate equity interests or creation of a trust as well as establishment of short positions by granting to third parties
the Convertible Bonds granted to the Allottee as well as comparable offsetting transactions that are economically equivalent to a sale of the Convertible Bonds are also prohibited. 

  

	(3)	Any violation of paragraphs (1) and/or (2) of this § 12 results in forfeiture of the Convertible Bonds. To the extent that the Company or the Allottees have substantive reasons, the
Management Board, in agreement with the Supervisory Board, may consent to dispositions of the Convertible Bonds in the form described in paragraphs (1) and (2) of this § 12. 

  

	(4)	Notwithstanding paragraphs (1) and (2) of this § 12, the Allottee is authorized, after expiration of the two-year waiting period or after expiration of the cancellation period specified
in the convertible bond certificates, to sell his/her Convertible Bonds to a credit institution to be specified by the Company. 

  
 § 13 
 Succession 
  

	(1)	The Convertible Bonds – provided they have not been cancelled pursuant to § 14 hereof – may be transferred by will or the laws of descent and distribution. The heirs shall be
bound by these terms and conditions. 

  

	(2)	The heirs shall report their standing as heirs to the Company and must prove their legitimacy in conformity with § 35 GBO. 

  
 § 14 
 Vesting Period; Cancellation of the Convertible Bonds 
  

	(1)	 The Convertible Bonds may in principle be cancelled for a maximum period of up to four (4) years (the “Vesting Period”). Expiration of the Vesting Period in
relation to the conversion privileges granted in total to the Allottee does not take place uniformly, but is divided into stages over the Vesting Period. One quarter of the Convertible Bonds becomes uncancellable each year, calculated from the
beginning of the vesting period. The Vesting Period begins to run with the issuance of the convertible bonds. A different Vesting Period may be specified by the Management Board for each individual case on the basis of internal guidelines of the

  

 6 

	 	 
Company that may be formulated thereby for common application and notified to the Allottee in the offer letter. Above and beyond this, the expiration of the Vesting
Period – if certificates evidencing the conversion privilege are issued – is noted in the respective certificates. 

  

	(2)	The Company or second-tier enterprises currently affiliated with it or in the future may immediately cancel the conversion privileges that are still subject to the Vesting Period without
compensation if the Allottee’s employment has been terminated prior to expiration of the Vesting Period specified for the conversion privileges. The cancellation of conversion privileges becomes effective upon receipt of a separate written
cancellation declaration by the Allottee, but not earlier than: 

  

	 	a)	in the case of an ordinary termination by the Allottee, upon receipt of his/her termination notice; 

  

	 	b)	in the case of an ordinary termination of the Allottee by the Company, upon effectiveness of such termination (termination of employment) or – in the case of the exoneration of the
Allottee – on the date of such exoneration; 

  

	 	c)	in the case of termination by the Allottee for cause, on the date on which the ordinary termination – defined as the termination notice by the Company or by a second-tier enterprise
currently affiliated with it or in the future on the date of the termination notice by the Allottee – would have become effective; 

  

	 	d)	in all other cases, on the date of actual termination of employment (for example, termination by rescission contract, death, retirement, educational leave of absence and similar reasons).

  

	(3)	The Company or a second-tier enterprise affiliated currently with it or in the future may cancel the conversion privileges no longer subject to a Vesting Period without compensation if

  

	 	a)	the Allottee has not exercised his/her conversion privileges within 12 calendar months after the cancellation according to paragraph (2) above becomes effective, or 

 

	 	b)	the Allottee has not exercised his/her conversion privileges within 12 months after the second-tier affiliated enterprise employing the Allottee has relinquished its affiliation with the
group (equity interest less than 50% in the equity or Share capital), 

  
 Provided such exercise would have been possible subject to the waiting period set forth in § 5 hereof and the exercise periods set forth in § 6 hereof. If an exercise of the conversion privileges according to
§§ 5 and 6 hereof is not possible on the effective date of the termination, the period begins when the exercise prerequisites of §§ 5 and 6 hereof exist for the first time. 
  

	(4)	The Management Board may, in isolated cases, choose not to cancel all or part of the conversion privileges if such cancellation seems inequitable in such isolated cases (suspension of
employment because of a maternity or paternity leave of absence, general disability, retirement and similar reasons). The same shall apply mutatis mutandis if the conversion privileges are intended to substitute for a severance payment that may be
due upon termination of employment or officer status. In individual cases, the choice not to cancel the conversion privileges may be made contingent upon the extension of the Vesting Period by the duration of the suspension of employment (for
example, due to a maternal or paternal leave of absence or an unpaid leave of absence). 

  

 7 

	(5)	In the event that the employment and/or the officer status of an Allottee with the Company or with a second-tier enterprise currently affiliated with it or in the future is –
irrespective of the reason – terminated, but at the same time a new employment or officer status is established with the Company or with a second-tier enterprise currently affiliated with it or in the future, the aforementioned cancellation
rights shall not apply on the occasion of such termination but only relative to any termination of the new employment or new officer status. 

  

	(6)	The Company has the right to cancel the conversion privileges with immediate effect if and as soon as insolvency proceedings are instituted against the assets of the Allottee, institution of
insolvency proceedings is declined for insufficiency of assets or conversion privileges are attached by a creditor and the enforcement measure is not rescinded within six (6) months (with expiration of the 6-month period). 

 

	(7)	For his/her part, the Allottee may cancel the conversion privilege with three-months notice as of the end of a quarter without having to give any reasons. 

  

	(8)	The Company may request the return of any issued and cancelled convertible bond certificates from the Allottee or from any other possessor. 

  
 § 15 
 Taxes 
  
 The Allottee himself/herself
shall pay all taxes that may be incurred in connection with the issuance or exercise of conversion privileges, including church taxes and solidarity surcharge. However, the Company shall deduct such taxes and charges from the Allottee’s salary
to the extent legally prescribed and pay them over, if appropriate in the form of wage-tax withholding, to the tax office having jurisdiction over its permanent establishment. Above and beyond this, the Company may, if necessary, make the issuance
of Shares contingent upon proof of appropriate tax payments by the Allottee or upon lodging of reasonable surety. If the Allottee does not or cannot meet his/her obligations stipulated by this § 15 hereof, the Company has to so report to the
tax office having jurisdiction over its permanent establishment. 
  
 § 16 
 Insider Rules 
  

	(1)	The Company hereby advises each Allottee that such Allottee may be subject to insider regulations and under certain circumstances may be punishable for disregard of these regulations. In
particular, insiders are prohibited from selling any Shares acquired through the exercise of conversion privileges by exploiting their knowledge of insider facts (§ 14(1) WpHG). 

  

	(2)	The Allottee hereby undertakes to acknowledge and honor any current or future internal guidelines published by the Company with respect to the prevention of insider violations. Any violation
of such guidelines is a breach of the accessory obligations defined by labor law and may give rise to, possibly immediate, termination of the Allottee’s employment. 

  
 § 17 
 Reservation of
Voluntary Nature 
  
 Any issuance of conversion privileges is voluntary in nature and an
Allottee who has been issued conversion privileges does not, by reason of such issuance, accrue any right to receive additional conversion privileges at any point in the future. 
  

 8 

 
§ 18 
 Exercise Agent 
  
 The exercise agent is the Management Board of the Company. The Management Board empowers the Legal
Department to accept subscription declarations and to handle the exercise procedure. In addition, the Company has the right to appoint a trustee (such as a bank), which in this respect assumes the tasks of the Management Board and functions as the
exercise agent. 
  
 § 19 
 Announcements 
  
 Declarations, notices, amendments or adjustments in regard to the conversion privileges are announced to the Allottee in writing. Written announcements of legally binding nature (such as cancellation declaration, adjustment of
the conversion price and similar information) are effected by personal delivery with acknowledgment of receipt or by registered letter or messenger to the address last reported by the Allottee to the Company or to the second-tier enterprise
affiliated with it. 
  
 § 20 
 Miscellaneous Provisions 
  

	(1)	Should any of these terms and conditions be or become invalid or unenforceable, in part or in whole, such provision shall be replaced by such valid and enforceable provision that, in a
legally permissible manner, matches as closely as possible the invalid or unenforceable provision, attaining the same or a similar economic effect. The invalidity or unenforceability of any provision hereof shall not affect the validity or
enforceability of any other provision hereof, which shall remain in full force and effect. The same shall apply mutatis mutandis if a loophole requiring amplification is discovered during execution of these terms and conditions.

  

	(2)	Amendments and additions to these conditions shall be in writing, unless recording by a notary is required. The foregoing sentence applies mutatis mutandis to any amendments of this

	 	§ 20(2). 

  

	(3)	The place of performance and place of jurisdiction is the registered seat of the Company. 

  

	(4)	The form and content of the conversion privileges as well as the rights and obligations of the Allottees and of the Company are construed in accordance with the laws of the Federal Republic
of Germany. 

  
 Martinsried/Planegg, September 30, 2004 
  
 The Management Board of 
 GPC Biotech AG 
  

	
	 Duly noted:
  
  

  

 9Terms and Conditons for Stock Appreciation Rights

 Exhibit 4.35 
  
 GPC Biotech AG 
 Martinsried/Planegg 
  
 Incentive Rights Terms and Conditions 
 for Members of the Supervisory Board 
  
 (Resolution of the Shareholder Meeting August 31, 2004) 
  
 Preamble 
  
 At the Annual Shareholders Meeting held on August 31, 2004, a resolution was passed to grant long-term variable compensation in the form of incentive rights (“Incentive Rights”) to members of the Supervisory Board.
The amount, terms and conditions of these Incentive Rights are as follows: 
  
 § 1 
 Grant of Incentive Rights 
  
 The Beneficiary is hereby granted              Incentive Rights as of September 1, 2004 (the “issue date”).
One Incentive Right represents the right to receive payment of the exercise price less the basic price after the end of the holding period. 
  
 § 2 
 Basic Price, Exercise Price 
  

	(1)	The basic price equals the average closing price of GPC Biotech ordinary shares at the XETRA closing auction of the Frankfurt Stock Exchange for the five trading days preceding the issue date
and the five trading days following the issue date. 

	(2)	The exercise price corresponds to the average closing price of GPC Biotech ordinary shares at the XETRA closing auction of the Frankfurt Stock Exchange for the 60 trading days following the
end of the holding period. 

	

	(3)	The exercise payment is due 100 calendar days after the end of the holding period. 

  
 § 3 
 Holding Period 
  

	(1)	The holding period for the Incentive Rights begins on the issue date and ends with the marketing approval of satraplatin by the FDA or the EMEA, whichever occurs first.

	(2)	 In the case of a change in control of the company, as defined in the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz), the holding
period 

	 	 
will end on the date of effectiveness of the acquisition. In this case, the 60 trading days directly preceding the acquisition date will be used to determine the
exercise price. The exercise price is due 100 days following the holding period. 

  
 § 4 
 Non-Transferability of Incentive Rights 
  
 Transfer of the Incentive Rights, including assignment, sale, pledge, grant of sub-rights or the
establishment of a trust, is forbidden. Any transaction that is economically comparable to a sale of the Incentive Rights is also forbidden and will lead to a forfeiture of the granted Incentive Rights without replacement. 
  
 § 5 
 Cancellation of Incentive Rights 
  
 The
Beneficiary will receive the full exercise price only if he or she is still a member of the Supervisory Board or the respective committee at the end of the holding period. If the Beneficiary leaves the Supervisory Board or the respective committee
before the end of the holding period, the Beneficiary will receive only a pro-rated exercise price. The pro-rated exercise price will be determined based on the length of the term of office, or membership on a committee, during the holding period in
proportion to the full holding period. 
  
 Martinsried/Planegg, September 1, 2004

  
 The Management Board of 
 GPC Biotech AG 
  

	
	 Agreed:
  

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]